ADAPT for COVID Act
Summary
Accelerated Drug Approval for Prescription Therapies for Coronavirus Act or the ADAPT for COVID Act This bill authorizes the Food and Drug Administration (FDA)to create an expedited drug approval process specifically for drugs that are currently approved for sale in certain countries (i.e., a European Economic Area member country, Australia, Canada, Israel, Japan, New Zealand, South Africa, or Switzerland) and meet certain criteria. Such criteria shall include establishing that (1) the drug is safe and effective, (2) all relevant U.S. patents or legal exclusivities have expired, and (3) the drug is intended to treat or prevent COVID-19 or another disease of epidemic potential. The FDA must process and review an application under this bill within 180 days of submission.
Bill status
in committee
1 of 4 stages cleared
Introduction
Oct 2021
Committee Review
Floor Vote
President
Introduced Oct 7, 2021
Last action Oct 7, 2021
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
2
Key actions
0
Committee
1
Oct 7, 2021
Committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
upper
Oct 7, 2021
Introduced
Introduced in Senate
upper
1 primary · 0 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Mike Braun
RRepublican
Ask Maddy
·
AI policy assistant
Ask Maddy about S 2983
Scope: US
Hi! I can help you understand S 2983. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline